| Literature DB >> 31766622 |
Ignacio Ruz-Caracuel1, Jorge L Ramón-Patino2, Álvaro López-Janeiro1, Laura Yébenes1,3, Alberto Berjón1,3, Alicia Hernández4, Alejandro Gallego2,5, Victoria Heredia-Soto5,6, Marta Mendiola3,6, Andrés Redondo2,5,7, Alberto Peláez-García3, David Hardisson1,3,7.
Abstract
Low-grade and early Federation for Gynecology and Obstetrics (FIGO) stage endometrioid endometrial carcinomas (EEC) have an excellent prognosis. However, approximately 10% of patients develop recurrence, which cannot be correctly predicted at diagnosis. We evaluated myoinvasive patterns as a prognostic factor of relapse in low-grade, early-stage EEC. Two-hundred and fifty-eight cases were selected according to the following inclusion criteria: (i) endometrioid endometrial carcinomas, (ii) grade 1 or 2 with (iii) FIGO stage I or II, and (iv) clinical follow-up. Slides were reviewed to annotate the myoinvasive pattern present in each case (infiltrative glands, microcystic, elongated and fragmented -MELF-, broad front, adenomyosis-like and adenoma malignum). Microsatellite instability was studied by immunoexpression of mismatch repair proteins (MLH1, PMS2, MSH2, and MSH6). There were 29 recurrences (11.2%) among the 258 cases analysed. A predominant broad front myoinvasive pattern was significantly associated with tumour relapse (p = 0.003). The presence of a pattern of infiltrative glands (p = 0.001) and microsatellite instability (p = 0.004) were associated with lower disease-free survival, without having an impact on overall survival. Our observations suggest the potential value of the pattern of myoinvasion as a prognostic factor in low-grade, early-stage endometrioid endometrial carcinoma.Entities:
Keywords: early stage; endometrial carcinoma; microsatellite instability; mismatch repair protein; myoinvasive pattern; prognosis
Year: 2019 PMID: 31766622 PMCID: PMC6966575 DOI: 10.3390/cancers11121845
Source DB: PubMed Journal: Cancers (Basel) ISSN: 2072-6694 Impact factor: 6.639
Clinicopathological characteristics of the study population.
| Parameter | Total ( | No Recurrence ( | Recurrence ( |
| |
|---|---|---|---|---|---|
|
| 63.96 ± 10.31 | 63.54 ± 10.45 | 67.28 ± 8.64 | 0.039 | |
|
| |||||
| <60 y. | 94 (36.4%) | 88 (38.4%) | 6 (20.7%) | 0.065 | |
| ≥60 y. | 164 (63.6%) | 141 (61.6%) | 23 (79.3%) | ||
|
| |||||
| IA | 182 (70.5%) | 171 (74.7%) | 11 (37.9%) | <0.001 | |
| IB | 67 (26.0%) | 51 (22.3%) | 16 (55.2%) | ||
| II | 9 (3.5%) | 7 (3.1%) | 2 (6.9%) | ||
|
| |||||
| G1 | 201 (77.9%) | 183 (80.3%) | 18 (62.1%) | 0.029 | |
| G2 | 56 (21.7%) | 45 (19.7%) | 11 (37.9%) | ||
|
| |||||
| None | 56 (21.71%) | 56 (24.5%) | 0 | <0.001 | |
| Inner half | 131 50.76%) | 120 (52.4%) | 11 (37.9%) | ||
| Outer half | 71 (27.5%) | 53 (23.1%) | 18 (62.1%) | ||
|
| |||||
| Present | 39 (15.1%) | 28 (12.2%) | 11 (37.9%) | 0.001 | |
| Absent | 219 (84.9%) | 201 (87.8%) | 18 (62.1%) | ||
|
| |||||
| Present | 64 (24.8%) | 53 (23.1%) | 11 (37.9%) | 0.085 | |
| Absent | 194 (75.2%) | 176 (76.9%) | 18 (62.1%) | ||
|
| |||||
| Present | 91 (35.3%) | 80 (34.9%) | 11 (37.9%) | 0.727 | |
| Absent | 167 (64.7%) | 149 (65.1%) | 18 (62.1%) | ||
|
| |||||
| Non infiltrative | Present | 56 (21.7%) | 56 (24.5%) | 0 | 0.003 |
| Absent | 202 (78.3%) | 173 (75.5%) | 29 (100%) | ||
| Infiltrating glands | Present | 130 (50.4%) | 114 (49.8%) | 16 (55.2%) | 0.600 |
| Absent | 128 (49.6%) | 115 (50.2%) | 13 (44.8%) | ||
| MELF | Present | 18 (7.0%) | 17 (7.4%) | 1 (3.4%) | 0.703 |
| Absent | 240 (93.0%) | 212 (92.6%) | 28 (96.6%) | ||
| Broad front | Present | 27 (10.5%) | 18 (7.9%) | 9 (31.0%) | 0.003 |
| Absent | 231 (89.5%) | 211 (92.1%) | 20 (69%) | ||
| Adenomyosis-like | Present | 26 (10.1%) | 23 (10.0%) | 3 (10.3%) | 1.00 |
| Absent | 232 (89.9%) | 206 (90.0%) | 26 (89.7%) | ||
| A. malignum | Present | 1 (0.4%) | 1 (0.4%) | 0 | |
| Absent | 257 (99.6%) | 228 (99.6%) | 29 (100%) | ||
|
| |||||
| Present | 158 (61.2%) | 135 (59.0%) | 23 (79.3%) | 0.036 | |
| Absent | 100 (38.8%) | 94 (41.0%) | 6 (20.7%) | ||
|
| |||||
| Present | 30 (11.6%) | 28 (12.2%) | 2 (6.9%) | 0.547 | |
| Absent | 228 (88.4%) | 201 (87.8%) | 27 (93.1%) | ||
|
| |||||
| Stable | 168 (84.4%) | 152 (86.9%) | 16 (66.7%) | 0.030 | |
| Unstable | 31 (15.6%) | 23 (13.1%) | 8 (33.3%) | ||
FIGO, International Federation of Obstetrics and Gynaecology; MELF, microcystic, elongated and fragmented glands; A. malignum, adenoma malignum.
Figure 1Myoinvasive patterns present in endometrioid endometrial carcinomas. (A) Non infiltrative, tumour is confined to the endometrium and does not invade the myometrium. (B) Infiltrative glands, composed of single or small groups of glands with irregular contours scattered in the myometrium. (C) Microcystic, elongated and fragmented glands (MELF) identified at the leading edge of the tumour associated with neutrophils infiltrate. (D) Adenomyosis-like, composed of groups larger than five glands with round borders within myometrium simulating adenomyosis. (E) Broad front, which has a linear limit between the tumour and the stroma beneath. (F) Adenoma malignum is composed of low cytological grade, regular, rounded, and widely spaced glands.
Associations between myoinvasive patterns, microsatellite status, and morphological parameters.
| Parameter | Microsatellite Instability | Mucinous Differentiation | Squamous Differentiation |
|---|---|---|---|
| Total number of cases analysed | 199 | 258 | 258 |
| Total number of positive cases (%) | 31 (15.58) | 64 (24.8) | 91 (35.3) |
| Infiltrative glands predominant pattern | 19 ( | 34 ( | 50 ( |
| MELF predominant pattern | 1 ( | 8 ( | 9 ( |
| Broad front predominant pattern | 4 ( | 5 ( | 11 ( |
| Adenomyosis-like predominant pattern | 4 ( | 8 ( | 8 ( |
| Presence of infiltrative glands pattern | 25 ( | 43 ( | 65 ( |
| Presence of MELF pattern | 2 ( | 15 ( | 17 ( |
Univariate analyses of odds ratios in the logistic regression model with relapse as the dependent variable.
| Parameter | Odds Ratio (CI 95%) | |
|---|---|---|
|
| ||
| Age ≥ 60 years | 2.392 (0.937–6.107) | 0.068 |
| Tumour grade 2 | 2.485 (1.097–5.631) | 0.029 |
| FIGO stage ≥IB | 3.065 (1.658–5.667) | <0.001 |
| Lymphovascular space invasion | 4.387 (1.879–10.242) | 0.001 |
| Infiltrative glands predominant pattern | 1.242 (0.571–2.699) | 0.585 |
| MELF predominant pattern | 0.445 (0.057–3.477) | 0.440 |
| Broad front predominant pattern | 4.751 (1.833–12.314) | 0.001 |
| Adenomyosis-like predominant pattern | 1.033 (0.290–3.681) | 0.960 |
| Presence of infiltrative glands pattern | 2.669 (1.047–6.807) | 0.040 |
| Presence of MELF pattern | 0.532 (0.120–2.359) | 0.406 |
| Mucinous differentiation | 2.029 (0.902–4.564) | 0.087 |
| Squamous differentiation | 1.138 (0.513–2.527) | 0.750 |
| Microsatellite instability | 3.304 (1.271–8.589) | 0.014 |
Multivariate analyses of odds ratios in the logistic regression model with relapse as the dependent variable.
| Parameter | Odds Ratio (CI 95%) | |
|---|---|---|
|
| ||
| Age ≥ 60 years | 2.772 (0.722–10.641) | 0.137 |
| Tumour grade 2 | 2.103 (0.700–6.324) | 0.186 |
| FIGO Stage ≥IB | 1.722 (0.161–18.383) | 0.653 |
| Lymphovascular space invasion | 2.729 (0.884–8.424) | 0.081 |
| Broad front predominant pattern | 17.302 (3.482–85.985) | <0.001 |
| Presence of infiltrative glands pattern | 1.981 (0.497–7.895) | 0.333 |
| Microsatellite instability | 1.453 (0.422–4.996) | 0.553 |
Figure 2Kaplan–Meier curves for disease-free survival (DFS) and overall survival (OS) according to the predominant pattern of myoinvasion, the presence of infiltrative glands myoinvasive pattern, and microsatellite instability (MSI). DFS (A) and OS (B) in relation to the predominant myoinvasive pattern. DFS (C) and OS (D) according to the presence of the infiltrative glands myoinvasive pattern. DFS (E) and OS (F) in microsatellite unstable versus stable cases.